Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1197364/full, but it redirected us to https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1197364/full. The analysis below is for the second page.

Title[redir]:
Frontiers | Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Description:
During the past decade, there has been a revolution in cancer therapeutics by the emergence of antibody-based immunotherapies that modulate immune responses ...

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Science
  • Education

Content Management System {πŸ“}

What CMS is doi.org built with?


Doi.org operates using TYPESETTER CMS.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

🌍 Impressive Traffic: 500k - 1M visitors per month


Based on our best estimate, this website will receive around 600,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We find it hard to spot revenue streams.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {πŸ”}

text, doi, crossref, full, google, scholar, abstract, pubmed, patients, iraes, cells, cancer, immune, ctla, ici, checkpoint, mice, autoimmune, cell, preexisting, immunotherapy, adverse, inhibitors, treatment, melanoma, events, disease, increased, activation, development, therapy, immunerelated, study, developed, oncol, blockade, treated, showed, clin, studies, tumor, clinical, survival, diseases, pdl, icis, response, association, immunol, role,

Topics {βœ’οΈ}

c57bl/6lpr/lpr-pd-1-/- mice resembled t-bet+rorΞ³t+ th17/1 effectors c57bl/6-lpr/lpr-pd-1-/- mice compared resembled graft-versus-host disease dress/drug-induced hypersensitivity syndrome complement-dependent antibody-mediated cytotoxicity pd-1/pd-l1 blocking compounds balb/c-rag-2-/-pd-1-/- mice anti-cytotoxic t-lymphocyte antigen-4 ctla-4f/fcd19cre/+ mice led pd-1/pd-l1 blockade induces c57bl/6lpr/lpr mice inhibitory pathway pd-1/pd-l1 nih/nci grants ca238263 itim motif-carrying immunoreceptor immune-related adverse events single-cell immune landscape mrl-faslpr/lpr mouse steroid-sparing biologic immunosuppressants anti-thyroid peroxidase antibodies pre-existing auto-antibodies immune-related adverse effects treatment-related adverse events releasing free pd-l1 including stevens-johnson syndrome potential flair-ups due t-cell checkpoint blockade open-access article distributed pre-treatment faucal abundance cardiovascular-related adverse effects positive anti-nuclear antibody adjuvant anti-pd-1 therapy real-world transverse study host cell pd-l1 foxp3-expressing treg cells cross-sectional study showed anti-programmed death-1 immunotherapy cell-driven plaque inflammation anti-ctla-4 blocking mab c57bl/6lpr/lpr mab-treated mice displayed pre-existing autoimmune disorders prolonged progression-free survival pd-1 receptor-deficient mice tumor necrosis factor-alpha peripheral t-cell tolerance nationwide multi-center cohort c57bl/6/pd-1-/- mice showed matched case-control study pre-existing autoimmune diseases

Schema {πŸ—ΊοΈ}

ScholarlyArticle:
      context:https://schema.org
      headline:Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
      author:
            type:Person
            name:Betul Ibis
            affiliation:
               Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
               Department of Medicine, Beth Israel Deaconess Medical Center, United States
            type:Person
            name:Konstantinos Aliazis
            affiliation:
               Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
               Department of Medicine, Beth Israel Deaconess Medical Center, United States
            type:Person
            name:Carol Cao
            affiliation:
               Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
               Department of Medicine, Beth Israel Deaconess Medical Center, United States
               Harvard College, United States
            type:Person
            name:Sasitorn Yenyuwadee
            affiliation:
               Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
               Department of Medicine, Beth Israel Deaconess Medical Center, United States
            type:Person
            name:Vassiliki A. Boussiotis
            affiliation:
               Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
               Department of Medicine, Beth Israel Deaconess Medical Center, United States
               Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, United States
      datePublished:2023-06-05
      dateModified:2025-07-02
      publisher:
         type:Organization
         name:Frontiers
      isPartOf:
         type:PublicationIssue
         datePublished:2023
         isPartOf:
            type:PublicationVolume
            volumeNumber:14
            isPartOf:
               type:Periodical
               name:Frontiers in Immunology
      citation:
         https://doi.org/10.3389/fimmu.2023.1197364
      inLanguage:en
Person:
      name:Betul Ibis
      affiliation:
         Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
         Department of Medicine, Beth Israel Deaconess Medical Center, United States
      name:Konstantinos Aliazis
      affiliation:
         Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
         Department of Medicine, Beth Israel Deaconess Medical Center, United States
      name:Carol Cao
      affiliation:
         Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
         Department of Medicine, Beth Israel Deaconess Medical Center, United States
         Harvard College, United States
      name:Sasitorn Yenyuwadee
      affiliation:
         Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
         Department of Medicine, Beth Israel Deaconess Medical Center, United States
      name:Vassiliki A. Boussiotis
      affiliation:
         Division of Hematology-Oncology Beth Israel Deaconess Medical Center, United States
         Department of Medicine, Beth Israel Deaconess Medical Center, United States
         Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, United States
Organization:
      name:Frontiers
PublicationIssue:
      datePublished:2023
      isPartOf:
         type:PublicationVolume
         volumeNumber:14
         isPartOf:
            type:Periodical
            name:Frontiers in Immunology
PublicationVolume:
      volumeNumber:14
      isPartOf:
         type:Periodical
         name:Frontiers in Immunology
Periodical:
      name:Frontiers in Immunology

Social Networks {πŸ‘}(7)

External Links {πŸ”—}(591)

Libraries {πŸ“š}

  • Vue.js

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Cloudflare
  • Crossref

6.45s.